-
[GWICC2009]吕树铮教授谈第七届冠心病介入沙龙新特点及TCT20...
《国际循环》:您能否简单介绍一下明年冠心病介入沙龙的情况?将有哪些新的改观?
作者:国际循环网
有100077人浏览
发布于:2009-10-15
-
[GWICC2009]Gerhard Hindricks 谈房颤治疗
International Circulation: You have a presentation about catheter ablation for atrial fibrillation at this meeting. Can you talk about where you see the direction of the treatment of atrial fibrillation heading? Do you think the indications for catheter ablation will be much broader in future than now?
作者:国际循环网
有60212人浏览
发布于:2009-10-15
-
[GWICC2009]Akira Matsumori 谈心衰标志物
作者:国际循环网
有82304人浏览
发布于:2009-10-15
-
[GWICC2009]William Louis谈降压策略
International Circulation: Blood pressure reduction is the key point in reducing cardiovascular risks. So how low should we lower the blood pressure? Is “as low as possible” a good strategy?《国际循环》:降压是减低心血管风险的关键,血压应该降到多低?“尽可能低”是个好策略吗?
作者:国际循环网
有60164人浏览
发布于:2009-10-15
-
[GWICC2009]霍勇教授谈心血管介入治疗培训新成就及国内新进...
《国际循环》:作为中华医学会心血管病介入治疗培训中心主任,您能否谈谈近年来国际间临床研究培训班取得的成绩。国际间的交流工作对国内临床工作的作用如何?
作者:国际循环网
有59457人浏览
发布于:2009-10-15
-
[GWICC2009]创新心绞痛药物治疗 改善患者预后
2009年10月10日,抗心绞痛新药尼可地尔的上市新闻发布会在第二十届长城会期间隆重举行。作为首个用于临床的ATP敏感的钾离子通道开放剂——尼可地尔,是以烟酰胺为基本骨架、同时具有硝酸基的化合物。与传统的硝酸酯类药物相比,不仅能有效控制各种类型的心绞痛,还可以显著减少心血管事件,改善病人预后。
作者:国际循环网
有26432人浏览
发布于:2009-10-15
-
[GWICC2009]全新规范 全面保护
2009年10月10日,在第二十届长城国际心脏病学会议上,令人期待已久的《β肾上腺素能受体阻滞剂的规范使用》一书终于与公众亮相,这成为本届长城会中的亮点之一,不仅赢得广大基层医生的瞩目,同时也受到诸多媒体的关注。作为国内首部系统介绍β肾上腺素能受体阻滞剂(β阻滞剂)的专著,该书将为各层次临床医生在使用β阻滞剂治疗相关疾病时提供一本案头的工具书和切实的临床用药指导。
作者:国际循环网
有23754人浏览
发布于:2009-10-15
-
[GWICC2009]ESC主席Roberto Ferrari教授谈中欧心率调查项目 ...
International Circulation: At this great wall conference, the ESC-CSC heart rate investigation project called CLARIFY has been initiated. Could you please give us a brief introduction of this project? What are the rationale, design and objective of this project?《国际循环》:在这次长城会议上,启动了名为CLARIFY中欧心率调查项目的研究,能请您简要介绍下这个项目吗?
作者:国际循环网
有63924人浏览
发布于:2009-10-15
-
[GWICC2009]杨新春教授谈急性冠脉综合征的临床治疗新进展
《国际循环》:能否请您谈谈对于急性冠脉综合征临床治疗的新进展?对临床指导意义如何?在其介入治疗方面有否新的突破和热点?
作者:国际循环网
有46640人浏览
发布于:2009-10-15
-
[GWICC2009]Jack Lewin谈NCDR
International Circulation: I’m here with Professor Jack Lewin. I’d like to thank you for joining us today, professor. It is a great honor having you here. At first I’d like to ask you the NCDR provides the most comprehensive cardiovascular data registry, representing a very large patient population and millions of records in the US. And this makes significant impact on clinical practice. So could you comment on the recent research projects of NCDR that you think are the most influential perhaps or most important something that we should know about?
作者:国际循环网
有113284人浏览
发布于:2009-10-14